ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2015 Financial Results
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 24, 2015, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2015, the third quarter of its 2015 fiscal year. Management will also provide an update on the Company and the financial guidance.
To access the live call by phone, dial 913-312-0966; the conference ID is 2370723. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through May 8, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche’s Kadcyla® is the first marketed product with ImmunoGen’s ADC technology. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
[email protected]
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Premier Financial (PFC) Tops Q1 EPS by 3c
- Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!